Business, energy, technology, markets and global industry news from Business News Today

CLDN18.2

PharmaDeviceNews CLDN18.2
AstraZeneca’s investigational CLDN18.2 antibody-drug conjugate sonesitatug vedotin improved overall survival in a Phase 3 trial involving previously treated advanced gastric and gastroesophageal junction cancers, although the progression-free survival endpoint was not statistically significant. Representative image.
Pharma & Biotech

Sonesitatug vedotin Phase 3 survival win strengthens AstraZeneca’s gastric cancer ADC strategy

Read why AstraZeneca’s sonesitatug vedotin survival win in CLDN18.2-positive gastric cancer is tempered by a Phase 3 PFS miss.

Read More
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.

Read More
Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.
Pharma & Biotech

Why CLINCH-3 matters for Antengene’s oncology strategy and gastric cancer ambitions

Antengene’s ATG-022 enters pivotal testing in gastric cancer, testing whether CLDN18.2 ADCs can stand out in a crowded oncology field.

Read More
Pharma & Biotech

Phanes’ spevatamig shows 40% response rate in mPDAC: How it compares to GnP standard

Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.

Read More